In a prospective evaluation from patients enrolled in the RAVE trial, the three chemokines matrix metalloproteinase 3 (MMP-3), tissue inhibitor of metallopeptidase inhibitor 1 (TIMP-1), and B-lymphocyte chemoattractant chemokine (C-X-C motif) ligand 13 (CXCL13) were able to distinguish active disease from remission with an AUC of 0.8 and a likelihood ratio of 4.3–4.6, which makes them promising candidates for further evaluation [96]. Here, MMP3 is linked to glycogen storage disease VI.